Methods for producing antibody-based therapeutics with enhanced ADCC activityare disclosed. The enhanced ADCC activity is attributed to oligomannose- typeN/-glycans on the antibodies and Fc fusion proteins of the invention. Alsodisclosed are methods of using such antibody-based therapeutics for targetedkilling of cells in a mammal, including therapeutic methods of treatingcancers, autoimmune diseases and other diseases.